Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 8/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.43 |
| ▸ | MLYCD | O95822 | 8/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879075 | 1.00 | NR1H3 (0.43) | NR1H3NR1H2MLYCDGAAMAPK1 | |
| SCHEMBL4422246 | 0.85 | NR1H2 (0.46) | NR1H3NR1H2MLYCDSMN1; SMN2LMNA | |
| SCHEMBL4422251 | 0.85 | NR1H2 (0.46) | NR1H3NR1H2MLYCDSMN1; SMN2LMNA | |
| SCHEMBL4431621 | 0.84 | MLYCD (0.44) | NR1H3NR1H2MLYCDGAAMAPK1 | |
| SCHEMBL4431625 | 0.84 | MLYCD (0.44) | NR1H3NR1H2MLYCDGAAMAPK1 | |
| SCHEMBL4876198 | 0.83 | NR1H2 (0.45) | NR1H3NR1H2MLYCDSMN1; SMN2LMNA | |
| SCHEMBL4876192 | 0.83 | NR1H2 (0.45) | NR1H3NR1H2MLYCDSMN1; SMN2LMNA | |
| SCHEMBL4882249 | 0.80 | NR1H3 (0.50) | NR1H3NR1H2MLYCD | |
| SCHEMBL4884853 | 0.80 | NR1H3 (0.50) | NR1H3NR1H2MLYCD | |
| SCHEMBL4882253 | 0.80 | NR1H3 (0.50) | NR1H3NR1H2MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-03-20 | — | — | US | claimed |
| US-7279477-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-09 | — | — | US | claimed |
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | MLYCD, ACACA, ME1 | NR1H3 1471/4885NR1H2 1305/4885MLYCD 1/4885 |
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | MLYCD, ME3, ACACA | NR1H3 1405/4885NR1H2 1233/4885MLYCD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.